Impedance Cardiography to Decrease the Risk of Preeclampsia
Public ClinicalTrials.gov record NCT03245970. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Use of Impedance Cardiography to Decrease the Risk of Preeclampsia
Study identification
- NCT ID
- NCT03245970
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- University of Tennessee Medical Center
- Other
- Enrollment
- Not listed
Conditions and interventions
Interventions
- Labetalol Hydrocholoride 200 mg orally every 12 hours Drug
- Nifedipine 60 mg orally daily Drug
- Atenolol 25 mg daily Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 51 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 23, 2017
- Primary completion
- Feb 28, 2020
- Completion
- Feb 28, 2020
- Last update posted
- Aug 4, 2020
2017 – 2020
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HIgh Risk Obstetrical Consultants | Knoxville | Tennessee | 37920 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03245970, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 4, 2020 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03245970 live on ClinicalTrials.gov.